Anyone who thinks that a 60 patient trial will be sufficient for the FDA regardless of the quality of the data is away with the fairies.
As far a credible reseach analyst pushing that view it just demonstrates that they infact have no credibility.
The company needs to come out in an announcement and disclose the trial(s) design, protocol and timetables clearly so that all of us can manage our own expectations.
to hotdat orphan drug ques for meeting on tues, page-3
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.0¢ |
Change
0.005(1.49%) |
Mkt cap ! $482.9M | |||
| Open | High | Low | Value | Volume |
| 33.5¢ | 34.0¢ | 33.0¢ | $313.9K | 939.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 135382 | 33.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.0¢ | 127709 | 13 |
View Market Depth
| Last trade - 11.29am 26/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |